Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,291,039 papers from all fields of science
Search
Sign In
Create Free Account
Combivent Respimat
Known as:
Respimat, Combivent
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Albuterol / Ipratropium
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
K. Steinmetz
,
Birgit Abenhardt
,
+4 authors
R. Buhl
International Journal of COPD
2019
Corpus ID: 196610744
Background Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early…
Expand
2018
2018
Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease - INHALATOR study.
Maria Vera Cruz de Oliveira
,
E. Pizzichini
,
+6 authors
N. Pinho
Respiratory Medicine
2018
Corpus ID: 53092239
2018
2018
Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study
S. Spila-Alegiani
,
F. Trotta
,
R. Da Cas
,
Mariangela Rossi
,
M. Venegoni
,
G. Traversa
COPD
2018
Corpus ID: 73458437
Abstract The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an open issue due to…
Expand
2018
2018
Клиническая и фармакоэкономическая оценка применения комбинации тиотропия бромида и олодатерола у пациентов с хронической обструктивной болезнью легких
С. К. Зырянов
,
Ю. А. Галатонова
2018
Corpus ID: 86609569
The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of…
Expand
2016
2016
Efficacité de l’olodatérol Respimat® (Striverdi Respimat®) sur la fonction respiratoire des patients BPCO : résultats de 2 études de 48 semaines
P. Girodet
,
G. T. Ferguson
,
+5 authors
P. Sachs
2016
Corpus ID: 78536577
2015
2015
The Budget Impact Of Duoresp® Spiromax® Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Italy: Estimated Impact Of…
S. Torvinen
,
J. Nicolai
,
+9 authors
A. Plich
Value in Health
2015
Corpus ID: 33910665
2015
2015
Tioropium+Olodaterol Respimat; Budget Impact In The Uk.
A. Ternouth
,
A. Tebboth
,
C. Selya-Hammer
,
N. González-Rojas Guix
Value in Health
2015
Corpus ID: 26623492
2015
2015
Neue ESC-Leitlinie berücksichtigt NOAK
feuchten Sprühwolke
,
D. Einecke
,
R. Hausmann
CME
2015
Corpus ID: 52799040
Anlässlich der europäischen Zulassung von Tiotropium/Olodaterol (Spiolto®) legte Prof. Dr. Klaus Rabe, Kiel, dar, dass die…
Expand
Highly Cited
2005
Highly Cited
2005
Respimat® Soft Mist™ Inhaler versus Hydrofluoroalkane Metered Dose Inhaler
W. Schürmann
,
S. Schmidtmann
,
Petra Moroni
,
D. Massey
,
Mahmud Qidan
Treatments in Respiratory Medicine
2005
Corpus ID: 11766837
IntroductionIn addition to offering favorable pharmaceutical performance, an ideal inhaler should be well accepted by patients…
Expand
2004
2004
Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat® Soft Mist™ Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma
W. Vincken
,
T. Bantje
,
M. Middle
,
F. Gerken
,
Diane Moonen
2004
Corpus ID: 72478172
ObjectiveRespimat® Soft Mist™ Inhaler (SMI) is a novel, propellant-free device that significantly increases lung deposition…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE